IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

TANDA, MARIA LAURA PIERA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.280
EU - Europa 6.359
AS - Asia 3.734
SA - Sud America 620
AF - Africa 58
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 14
AN - Antartide 1
Totale 23.081
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.130
IT - Italia 3.071
SG - Singapore 1.311
UA - Ucraina 863
CN - Cina 695
SE - Svezia 603
HK - Hong Kong 523
BR - Brasile 504
VN - Vietnam 481
DE - Germania 445
TR - Turchia 437
IE - Irlanda 321
GB - Regno Unito 282
FI - Finlandia 246
RU - Federazione Russa 187
CA - Canada 85
JP - Giappone 73
IN - India 70
FR - Francia 59
MX - Messico 58
PL - Polonia 43
AT - Austria 41
AR - Argentina 40
CZ - Repubblica Ceca 35
NL - Olanda 33
ES - Italia 30
ZA - Sudafrica 27
BD - Bangladesh 25
BE - Belgio 21
EC - Ecuador 21
CH - Svizzera 19
CL - Cile 19
IQ - Iraq 16
LT - Lituania 16
EU - Europa 14
ID - Indonesia 13
PK - Pakistan 12
AE - Emirati Arabi Uniti 11
IL - Israele 10
UZ - Uzbekistan 9
NZ - Nuova Zelanda 8
PE - Perù 8
RO - Romania 8
VE - Venezuela 8
CO - Colombia 7
NP - Nepal 7
PY - Paraguay 7
AU - Australia 6
KR - Corea 6
MA - Marocco 6
MY - Malesia 6
EG - Egitto 5
BY - Bielorussia 4
KE - Kenya 4
KG - Kirghizistan 4
TH - Thailandia 4
TN - Tunisia 4
UY - Uruguay 4
BG - Bulgaria 3
HR - Croazia 3
HU - Ungheria 3
JM - Giamaica 3
MD - Moldavia 3
PH - Filippine 3
PT - Portogallo 3
RS - Serbia 3
SA - Arabia Saudita 3
TW - Taiwan 3
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
CG - Congo 2
CI - Costa d'Avorio 2
DK - Danimarca 2
EE - Estonia 2
HN - Honduras 2
JO - Giordania 2
MK - Macedonia 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AQ - Antartide 1
AZ - Azerbaigian 1
BO - Bolivia 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GA - Gabon 1
GR - Grecia 1
KW - Kuwait 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
MO - Macao, regione amministrativa speciale della Cina 1
MU - Mauritius 1
NG - Nigeria 1
NO - Norvegia 1
PS - Palestinian Territory 1
QA - Qatar 1
SI - Slovenia 1
SR - Suriname 1
Totale 23.078
Salva come PNG Salva come JPEG
Città #
Milan 2.073
Fairfield 1.409
Dallas 1.219
Ashburn 1.071
Woodbridge 831
Chandler 737
Singapore 697
Jacksonville 684
Houston 671
Seattle 562
Wilmington 527
Hong Kong 516
Cambridge 451
Dearborn 367
Ann Arbor 354
Nyköping 322
Dublin 305
Princeton 302
Beijing 234
Izmir 216
Boardman 211
Rome 169
Dong Ket 164
Los Angeles 148
New York 140
The Dalles 126
Chicago 124
San Diego 102
Como 101
London 93
San Mateo 78
Munich 74
Tokyo 69
São Paulo 66
Ogden 60
Washington 57
Santa Clara 50
Helsinki 48
Redmond 48
Ho Chi Minh City 43
Warsaw 41
Hanoi 39
Hefei 39
Frankfurt am Main 35
Varese 34
Brno 33
Kunming 33
Toronto 30
Buffalo 29
Denver 29
Mexico City 29
Montreal 28
Atlanta 26
Düsseldorf 26
Guangzhou 26
Phoenix 26
San Francisco 25
Vienna 24
Turku 23
Chennai 22
Brooklyn 21
Brussels 21
Johannesburg 21
Nanjing 21
Norwalk 21
Orem 21
Salt Lake City 21
Nuremberg 20
Poplar 20
Shanghai 20
Cavaria con Premezzo 19
Stockholm 18
Berlin 17
North Bergen 17
Jinan 16
Manchester 16
Tampa 16
Belo Horizonte 15
Boston 14
Elk Grove Village 13
Turin 13
Ankara 12
Amsterdam 11
Charlotte 11
Council Bluffs 11
Falkenstein 11
Haiphong 11
Istanbul 11
Nanchang 11
Paris 11
Verona 11
Des Moines 10
Pune 10
Changsha 9
Columbus 9
Curitiba 9
Guayaquil 9
Kilburn 9
Madrid 9
Querétaro 9
Totale 16.691
Salva come PNG Salva come JPEG
Nome #
Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma 235
Simultaneous medullary and papillary thyroid cancer: two case reports. 233
Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study 232
Process to radioactive iodine treatment for Graves' hyperthyroidism: condemned or absolved? 226
Masked hypertension in newly diagnosed hypothyroidism: a pilot study 225
The phenotype of newly diagnosed Graves’ disease in Italy in recent years is milder than in the past: results of a large observational longitudinal study 224
Epidemiology, natural history, risk factors, and prevention of graves’ orbitopathy 224
Antithyroid drug treatment for Graves’ disease: baseline predictive models of relapse after treatment for a patient-tailored management 220
Cardiometabolic healthy and unhealthy obesity: does vitamin D play a role? 215
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study 210
Breast cancer and thyroid diseases: analysis of 867 consecutive cases 204
Disease heterogeneity in IgG4-related hypophysitis: report of two histopathologically proven cases and review of the literature 203
Graves' hyperthyroidism of recent onset and Graves' orbitopathy: to ablate or not to ablate the thyroid? 199
Arthropathy in acromegaly: a questionnaire-based estimation of motor disability and its relation with quality of life and work productivity 198
Nutrizione iodica e ipertiroidismo: quello che c’è da sapere 196
Pituitary apoplexy during pregnancy: A rare, but dangerous headache 196
Immunomodulatory effect of vitamin D and its potential role in the prevention and treatment of thyroid autoimmunity: a narrative review 195
Can combination of glucocorticoids with other immunosoppressive drugs reduce the cumulative dose of glucocorticoids for moderate-to-severe and active Graves' orbitopathy? 193
Continuous monitoring of the recurrent laryngeal nerve in thyroid surgery: a critical appraisal 190
Can a patient-tailored treatment approach for Graves' disease reduce mortality? 188
Oral steroid prophylaxis for Graves' orbitopathy after radioactive iodine treatment for Graves' disease is not only effective, but also safe 187
Outcome prediction of treatment of Graves' hyperthyroidism with antithyroid drugs 186
Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study 185
Physical performance in newly diagnosed hypothyroidism: a pilot study 184
Time interval in diagnosis and treatment of papillary thyroid cancer: a descriptive, retrospective study 183
Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial 180
Plasma total and acylated ghrelin concentrations in patients with clinical and subclinical thyroid dysfunction 179
Minimally invasive follicular thyroid cancer (MIFTC) - A consensus report of the European Society of Endocrine Surgeons (ESES) 179
Features and outcome of differentiated thyroid carcinoma associated with Graves' disease: results of a large, retrospective, multicenter study 179
Skeletal health in patients with differentiated thyroid carcinoma 179
Case report: multiple electrolyte disturbance with severe neurological manifestations induced by chronic use of PPIs 178
Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH) 177
Iodine supplementation in women of reproductive age: a survey of clinical practice among Italian gynecologists and midwives 172
Medullary thyroid carcinoma: surgical treatment advances 172
An update on medical management of Graves' ophthalmopathy 171
Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal 171
Thyroid cancer with tracheal invasion: A pathological estimation 171
Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. 170
Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association 170
Multidisciplinary Management of Intrathoracic Goiter: A Case Report 170
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group 167
The course of Graves' ophthalmopathy is not influenced by near total thyroidectomy: a case-control study 165
Shortening Hospital Stay for Thyroid Surgery. 163
Pituitary in black—hypopituitarism secondary to hemosiderosis 163
Thyroid hormone treatment for differentiated thyroid carcinoma: What drug, how long, what dose? 163
Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center 161
Potassium perchlorate only temporarily restores euthyroidism in patients with amiodarone-induced hypothyroidism who continue amiodarone therapy 156
Orbital radiotherapy for Graves' ophthalmopathy 156
Novel treatment modalities for Graves' orbitopathy 156
Add-On Effect of Selenium and Vitamin D Combined Supplementation in Early Control of Graves’ Disease Hyperthyroidism During Methimazole Treatment 156
Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: Results of a prospective, single-blind, randomized study 155
Thyroid vascularity and blood flow are not dependent on serum thyroid hormone levels:studies in vivo by color flow Doppler sonography 154
Effects of amiodarone, thyroid hormones and CYP2C9 and VKORC1 polymorphisms on warfarin metabolism: a review of the literature 151
An update on the pharmacological management of hyperthyroidism due to Graves' disease 150
Iopanoic acid rapidly controls Type I amiodarone-induced thyrotoxicosis prior to thyroidectomy 149
Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy 149
Treating Graves' orbitopathy: where are we? 149
Radioiodine and thyroid-associated ophthalmopathy 149
Analisi dei costi 149
Cigarette smoking and the thyroid 148
Medullary thyroid carcinoma: surgical treatment advances 146
Amiodarone and the thyroid 146
Orbital radiotherapy for Graves' ophthalmopathy 145
Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European Endocrinologists 145
Graves' ophthalmopathy 145
Changes in Autonomic Modulation to the Heart and Intracellular Catecholamines. A Longitudinal Study in Differentiated Thyroid Carcinoma during Short-Term Hypothyroidism and Thyroid Hormone Replacement. 144
Endpoints for screening thyroid cancer in the Republic of Korea: thyroid specialists' perspectives. 144
Thyroid autoimmunity and environment 143
Orbital radiotherapy for Graves' ophthalmopathy 143
Oxidative stress and Graves' ophthalmopathy: In vitro studies and therapeutic implications 142
Relationship between management of hyperthyroidism and course of the ophthalmopathy 142
Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations 142
Amiodarone-induced thyrotoxicosis: something new to refine the initial diagnosis? 142
Gastric Xanthomatous Hyperplastic Polyps – Just an Incidental Endoscopic Finding? 142
Amyloid goiter 141
Management of thyroid eye disease 140
Recent developments in the follow-up, prevention and management of complications in thyroid surgery 140
Relation between Graves' orbitopathy and radioiodine therapy for hyperthyroidism: facts and unsolved questions 139
A potential role of human RNASET2 overexpression in the pathogenesis of Graves’ disease 139
The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy 137
Efficacy and safety of orbital radiotherapy for Graves' orbitopathy 137
Novel approaches to the management of Graves' ophthalmopathy 136
Vitamin D, Chronic Migraine, and Extracranial Pain: Is There a Link? Data From an Observational Study 136
Cigarette smoking and treatment outcomes in Graves' ophthalmopathy 135
Amiodarone-unduced thyrotoxicosis. A review 134
La prevenzione dell'oftalmopatia basedowiana 133
Currently available somatostatin analogs are not good for Graves' orbitopathy 132
Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying 132
Position statement of the Microbiota International Clinical Society 131
Smoking and the Thyroid 131
Novel immunomodulating agents for Graves orbitopathy 130
Orbital decompression in Graves' ophthalmopathy by medial and lateral wall removal 130
Immunomodulatory role of vitamin D and selenium supplementation in newly diagnosed Graves' disease patients during methimazole treatment 128
When primary hyperparathyroidism comes as good news 127
Solitary intrathyroidal metastasis of renal clear cell carcinoma in a toxic substernal multinodular goiter. 127
Severità del Morbo di Basedow di prima diagnosi: ruolo dei linfociti Treg e dei micronutrienti. Dati preliminari di uno studio osservazionale pilota 124
Prevalence and natural history of Graves' orbitopathy in the XXI century 122
The iodine nutritional status in the Italian population: data from the Italian National Observatory for Monitoring Iodine Prophylaxis (OSNAMI) (period 2015–2019) 122
Autoimmune Thyroid Disease 120
Influence of new technologies on thyroid surgery: state of art 116
Totale 16.288
Salva come PNG Salva come JPEG
Categoria #
all - tutte 101.460
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 101.460
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.015 0 0 0 0 0 314 261 294 365 170 243 368
2021/20221.829 176 169 89 71 111 139 117 88 246 291 128 204
2022/20232.201 272 139 170 230 158 486 16 265 264 82 52 67
2023/20243.560 531 536 544 653 643 333 19 41 95 46 17 102
2024/20252.905 14 26 435 126 100 145 135 210 306 230 366 812
2025/20264.504 624 737 998 1.184 800 161 0 0 0 0 0 0
Totale 23.385